Distinct Estradiol and Follicle Stimulating Hormone Trajectory Patterns during the Menopausal Transi

来源 :BIT`s 2nd Annual World Congress of Endobolism-2012(2012第二届内分 | 被引量 : 0次 | 上传用户:hjx1000000
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Context: Variability in the pattern of change in estradiol (E2) and follicle stimulating hormone (FSH) levels over the menopause transition has not been well-defined.Objective: The current study aimed to determine whether different trajectories of E2 and FSH could be identified.Design: The Study of Womens Health Across the Nation (SWAN) is a longitudinal observational study of the menopausal transition with up to 10 annual follow-ups.Setting: Women aged 42-52 years from seven participating sites were recruited.Participants: Women with ≥3d 12 months amenorrhea that was not due to hysterectomy/oophorectomy and who were not using hormone therapy before the final menstrual period (FMP).Main Outcome Measures: Annual serum E2 and FSH levels anchored to FMP.Results: Four distinct E2 trajectories and three distinct FSH trajectories were identified.E2 trajectories were: Slow Decline (26.9%), Flat (28.6%), Low Rise (13.1%), and High Rise (31.5%).FSH trajectories were: Low (10.1%),Medium (48.1%), and High (41.9%) rising patterns.Obesity increased the likelihood to Flat E2 and Low FSH trajectories for all race/ethnic groups.Normal weight Caucasian and African American women tended to follow the High Rise E2 and High FSH trajectories.Normal weight Chinese/Japanese women followed the Slow Declining E2 and the High/Medium FSH trajectories.Conclusions: E2 and FSH trajectories over the menopausal transition are not uniform across women.Obesity and race/ethnicity affects the variation of E2 and FSH changing patterns.
其他文献
Introduction: Castration-resistant metastatic prostate cancer is a lethal disease for which no curative therapies exist.Despite improved understanding of many pathways and potential agents active in p
会议
Intensive research has been conducted towards developing more efficient and multifunctional drug delivery systems to deliver a therapeutic agent to a target site with amplified therapeutic value.Cance
会议
Epithelial-mesenchymal transition is the key process driving cancer metastasis.Oncogene/self renewal factor BMI-1 has been shown to induce EMT in cancer cells.Recent studies have implied that noncodin
会议
The present development of new therapies in oncology has been unlighted by the development of companion diagnostics.In general, 90% of drugs in the present therapeutic arsenal are only effective in 30
会议
Cigarette smoke is a major risk factor for bladder cancer and contributes to chemoresistance in bladder cancer patients who continue to smoke while receiving chemotherapy.Nicotine has been implicated
会议
Despite advances in chemotherapeutic regimens, the treatment of metastatic cancer remains a challenge.A key problem with chemotherapy drugs is nonspecific drug distribution, resulting in low tumour co
会议
In order to find one or more suppressors of tumor progression in vivo for head and neck squamous cell carcinoma (HNSCC), we searched for molecules down-regulated in HNSCC cells when the cells were tre
会议
CYP2D6 is the critical & prominent enzyme by which tamoxifen is metabolized to the active metabolite endoxifen.Recent literature suggests a minimal concentration threshold of 5.97 ng/mL of endoxifen i
会议
Neuroblastoma is an embryonic malignancy arising from neuroblasts.The mechanisms that regulate the origination of neuroblastoma are still not very clear.In this study, we revealed that 6-bromoindirubi
会议
PURPOSE: To determine the structural requirements for the transformation from estrogenic to anti-estrogenic compounds in a series of daidzein derivatives.DESIGN METHODS: A series of daidzein analogues
会议